The role of interferon as a modifier of epithelialmesenchymal transition in tumor cells

Experimental Oncology

Volumn 33, Issue 3, 2011, Pages 178-181

  Kudryavets, Yu I ^a   Bezdenezhnykh, N O ^a   Lykhova, O O ^a   Semesiuk, N I ^a   Vorontsova, A L ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA SMOOTH MUSCLE ACTIN; INTERFERON; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOLYSIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; IMMUNOCYTOCHEMISTRY; MESENCHYMAL EPITHELIAL TRANSITION; MESENCHYME CELL; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL;

ANIMALS; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTERFERONS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 80053431019     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
2. Wright JA, Richer JK, Goodall GJ. MicroRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 213-23.
3. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010; 126: 2575-83.
4. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
5. McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009; 28: 335-44.
6. M.Lee J, Dedhar S, Kalluri R, et al. The epithelialmesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-81.
7. Biological methods for treatment of cancer. DeVita T, Hellman C, Rosenberg AC, eds. Moskow: Meditsina, 2002; 920 p (In Russian).
8. Vilcek J. My fifty years with interferon. J Interferon Cytokine Res 2007; 27: 535-41.
9. Vorontsova AL, Kudryavets YI. Interferon as an important element in optimizing the treatment of cancer patients. Oncologiya 2000; 2: 16-24 (In Russian).
10. López-Ocejo O, Perea SE, Bequet-Romero M, et al. Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-alpha. Biochem Biophys Res Commun 2000; 277: 410-6.
11. Takahara T, Sugiyama K, Zhang LP, et al. Cotreatment with interferon-alpha and-gamma reduces liver fibrosis in a rat model. Hepatol Res 2004; 28: 146-54. (Pubitemid 38220224)
12. Kudryavets YuI, Bezdenezhnykh NO, Lukyanova NYu, et al. Modifying influence of prolonged action of interferon on phenotypic characteristics of human lung cancer cells in vitro. Exp Oncol 2008; 30: 283-8.
13. Agiostratidou G, Hulit J, Phillips GR, Hazan RB. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007; 12: 127-33. (Pubitemid 47215430)